Literature DB >> 29752391

ISCHEMIA: Establishing the Primary End Point.

Sripal Bangalore1, David J Maron2, Harmony R Reynolds3, Gregg W Stone4, Sean M O'Brien5, Karen P Alexander5, Judith S Hochman3.   

Abstract

Entities:  

Keywords:  clinical trial; follow-up studies; heart failure; humans; myocardial ischemia

Mesh：

Substances：

Year:  2018        PMID： 29752391      PMCID： PMC5967873          DOI： 10.1161/CIRCOUTCOMES.118.004791

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN： 1941-7713


× No keyword cloud information.
  9 in total

1.  Methods for mid-course corrections in clinical trials with survival outcomes.

Authors:  Thomas D Cook
Journal:  Stat Med       Date:  2003-11-30       Impact factor: 2.373

2.  Letter by Hochman and Maron Regarding Article, "'Faith Healing' and 'Subtraction Anxiety' in Unblinded Trials of Procedures: Lessons From DEFER and FAME-2 for End Points in the ISCHEMIA Trial."

Authors:  Judith S Hochman; David J Maron
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-04

Review 3.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.

Authors:  Karen A Hicks; Kenneth W Mahaffey; Roxana Mehran; Steven E Nissen; Stephen D Wiviott; Billy Dunn; Scott D Solomon; John R Marler; John R Teerlink; Andrew Farb; David A Morrow; Shari L Targum; Cathy A Sila; Mary T Thanh Hai; Michael R Jaff; Hylton V Joffe; Donald E Cutlip; Akshay S Desai; Eldrin F Lewis; C Michael Gibson; Martin J Landray; A Michael Lincoff; Christopher J White; Steven S Brooks; Kenneth Rosenfield; Michael J Domanski; Alexandra J Lansky; John J V McMurray; James E Tcheng; Steven R Steinhubl; Paul Burton; Laura Mauri; Christopher M O'Connor; Marc A Pfeffer; H M James Hung; Norman L Stockbridge; Bernard R Chaitman; Robert J Temple
Journal:  J Am Coll Cardiol       Date:  2018-03-06       Impact factor: 24.094

4.  Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study.

Authors:  Frederick L Brancati; Mary Evans; Curt D Furberg; Nancy Geller; Steven Haffner; Steven E Kahn; Peter G Kaufmann; Cora E Lewis; David M Nathan; Bertram Pitt; Monika M Safford
Journal:  Clin Trials       Date:  2012-02       Impact factor: 2.486

5.  Coronary intervention for persistent occlusion after myocardial infarction.

Authors:  Judith S Hochman; Gervasio A Lamas; Christopher E Buller; Vladimir Dzavik; Harmony R Reynolds; Staci J Abramsky; Sandra Forman; Witold Ruzyllo; Aldo P Maggioni; Harvey White; Zygmunt Sadowski; Antonio C Carvalho; Jamie M Rankin; Jean P Renkin; P Gabriel Steg; Alice M Mascette; George Sopko; Matthias E Pfisterer; Jonathan Leor; Viliam Fridrich; Daniel B Mark; Genell L Knatterud
Journal:  N Engl J Med       Date:  2006-11-14       Impact factor: 91.245

6.  Risk of mortality in relation to an updated classification of left ventricular geometric abnormalities in a general population: the Pamela study.

Authors:  Cesare Cuspidi; Rita Facchetti; Michele Bombelli; Carla Sala; Marijana Tadic; Guido Grassi; Giuseppe Mancia
Journal:  J Hypertens       Date:  2015-10       Impact factor: 4.844

7.  The Stroke Rehabilitation Assessment of Movement (STREAM): a comparison with other measures used to evaluate effects of stroke and rehabilitation.

Authors:  Sara Ahmed; Nancy E Mayo; Johanne Higgins; Nancy M Salbach; Lois Finch; Sharon L Wood-Dauphinée
Journal:  Phys Ther       Date:  2003-07

8.  Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.

Authors:  Bernard De Bruyne; Nico H J Pijls; Bindu Kalesan; Emanuele Barbato; Pim A L Tonino; Zsolt Piroth; Nikola Jagic; Sven Möbius-Winkler; Sven Mobius-Winckler; Gilles Rioufol; Nils Witt; Petr Kala; Philip MacCarthy; Thomas Engström; Keith G Oldroyd; Kreton Mavromatis; Ganesh Manoharan; Peter Verlee; Ole Frobert; Nick Curzen; Jane B Johnson; Peter Jüni; William F Fearon
Journal:  N Engl J Med       Date:  2012-08-27       Impact factor: 91.245

9.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Authors:  Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690
  9 in total
  4 in total

1.  Fractional flow reserve at the crossroad between revascularization and medical therapy.

Authors:  Carlos Collet; Patrick W Serruys
Journal:  Cardiovasc Diagn Ther       Date:  2018-08

2.  International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design.

Authors:  Sripal Bangalore; David J Maron; Jerome L Fleg; Sean M O'Brien; Charles A Herzog; Gregg W Stone; Daniel B Mark; John A Spertus; Karen P Alexander; Mandeep S Sidhu; Glenn M Chertow; William E Boden; Judith S Hochman
Journal:  Am Heart J       Date:  2018-08-01       Impact factor: 4.749

Review 3.  Unstable Angina as a Component of Primary Composite Endpoints in Clinical Cardiovascular Trials: Pros and Cons.

Authors:  Anna Meta Dyrvig Kristensen; Manan Pareek; Kristian Hay Kragholm; Thomas Steen Gyldenstierne Sehested; Michael Hecht Olsen; Eva Bossano Prescott
Journal:  Cardiology       Date:  2022-05-10       Impact factor: 2.342

4.  Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data.

Authors:  Frederik M Zimmermann; Elmir Omerovic; Stephane Fournier; Henning Kelbæk; Nils P Johnson; Martina Rothenbühler; Panagiotis Xaplanteris; Mohamed Abdel-Wahab; Emanuele Barbato; Dan Eik Høfsten; Pim A L Tonino; Bianca M Boxma-de Klerk; William F Fearon; Lars Køber; Pieter C Smits; Bernard De Bruyne; Nico H J Pijls; Peter Jüni; Thomas Engstrøm
Journal:  Eur Heart J       Date:  2019-01-07       Impact factor: 29.983
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.